Breakthrough Moments in Bronchiectasis: Exciting Updates from Dr. Daley

The past several days have been nothing short of inspiring for the bronchiectasis and NTM community.

Between new research updates, clinical insights, and groundbreaking treatment news, we have so much to be hopeful about!

It all began with a powerful video from Dr. Charles Daley of National Jewish Health, who was speaking with a patient group in Florida. His focus? The newly FDA-approved medication for bronchiectasis: Brensocatib (brand name BRINSUPRI™).

Why This Matters

For decades, people living with bronchiectasis have had limited treatment options beyond airway clearance and antibiotics. The FDA’s approval of Brensocatib marks the first new therapy specifically approved for non-CF bronchiectasis, and the ripple effects are already being felt in the bronchiectasis care centers across the country.

Dr. Daley explained that at National Jewish Health, clinicians will begin prescribing Brensocatib to patients who are most likely to benefit—including those who struggle with chronic infections like nontuberculous mycobacteria (NTM). Even more importantly, NJH will collect data from these patients to help determine the drug’s long-term effectiveness across different subgroups.

A Standout Finding

What truly lit up the conversation was one of the most exciting results from the pivotal clinical trial:

• At the 25 mg dose, patients taking Brensocatib maintained stable lung function.
  
  
• In contrast, those on placebo continued to experience a decline in lung function—a pattern that all too many of us living with bronchiectasis know too well.
  
  

Dr. Daley emphasized how encouraging this is, since preserving lung function is one of the most important goals in managing bronchiectasis. To see a therapy halt decline—not just reduce flare-ups—is a breakthrough worth celebrating.
​

A New Chapter of Hope

These updates (see video for complete talk) remind us that the field of bronchiectasis care is finally moving forward. We are not standing still. From clinical trials to FDA approval to real-world prescribing, there is momentum, hope, and possibility taking shape.

For patients, caregivers, and clinicians alike, this is the beginning of a new chapter—one where the words “stable lung function” carry the promise of more time, more strength, and more opportunities to live fully.

Click to learn more about BE CLEAR resources, including the book and individual consultations.
​